Market Overview

Asia-Pacific Colorectal Cancer Therapeutics Markets 2018-2024 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market -


The "Colorectal
Cancer Therapeutics in Asia-Pacific Markets to 2024 - Launch of Premium
Targeted Therapies and Increasing Prevalence to Drive the Market"

report has been added to's

The report "Colorectal Cancer Therapeutics in Asia-Pacific Markets
to 2024 - Launch of Premium Targeted Therapies and Increasing Prevalence
to Drive the Market"
details the key points (etiology,
epidemiology, current treatment, products currently marketed and in
pipeline, market drivers and barriers) driving the Colorectal Cancer
(CRC) market in the five Asia-Pacific (APAC) markets: India, China,
Australia, South Korea and Japan.

Many countries are facing the challenge of an aging population, and
there will be an increased number of people aged 50 and over, a
high-risk age range for Colorectal Cancer (CRC). Over half of the
incident cases of Colorectal Cancer (CRC) are diagnosed in patients over
the age of 50. Colorectal Cancer (CRC) is the most common cancer and the
leading cause of cancer-related mortality globally, accounting for 0.77
million deaths in 2015.

The five-year prevalence population for Colorectal Cancer (CRC) in
Asia-Pacific was 1.7 million in 2017. This figure has been gradually
rising with the growing elderly population and increasingly Westernized
lifestyles. However, growing awareness of the disease and associated
risk factors together with the availability of free testing services for
Colorectal Cancer (CRC) patients will increase early diagnosis and the
treatment-receiving population, including targeted treatment, driving
demand and contributing to market growth. Increasing affordability and
healthcare access in India and China are also likely to contribute to
the growth of the treatment-receiving pool significantly.

On the other hand, the poor prognosis, particularly for patients with
advanced disease, has created a pressing need for improved therapeutic
options. The Colorectal Cancer (CRC) market is therefore shifting from a
focus on generic chemotherapy regimens to a complex treatment landscape
based on the presence of various molecular aberrations. The marketed
products landscape comprises a wide range of treatment options,
including EGFR-targeted therapies, angiogenesis inhibitors, multiple
kinase inhibitors and new chemotherapies.

Market Dynamics


  • Increasing Elderly Population and Incidence of CRC
  • Increasing Screening Programs and Approval of New Screening Tests for
    CRC to Drive Early Diagnosis Rate
  • Increase in Mutation Testing to Drive Market Growth
  • Availability of Novel First-, Second- and Third-Line Therapy Options
    in Pipeline
  • Diversified Healthcare Reform to Boost Market Growth
  • Diversified Health Insurance System to Help Nurture Growth


  • Patent Expiration of Branded Therapies to Affect CRC Market Growth
  • High Prices of Therapeutics to Slow Down Market Growth
  • Limited Incorporation of Immunotherapies in the CRC Treatment Algorithm
  • Lack of Development of Neoadjuvant and Adjuvant Pipeline Products
  • Lack of Reimbursement and Penetration of Generic Drugs to Hinder
    Market Growth in China and India
  • Drug Pricing Reforms

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Marketed Products

4 Pipeline Analysis

5 Clinical Trial Analysis

6 Multi-scenario Forecast

7 Drivers and Barriers

8 Deals and Strategic Consolidations

9 Appendix

Companies Mentioned

  • Taiho Pharma
  • Merck KGaA
  • Amgen
  • Takeda
  • Roche
  • Eli Lilly
  • Sanofi
  • Regeneron
  • Bayer
  • Onyx
  • Bristol-Myers Squib
  • Sumitomo Dainippon Pharma
  • Array BioPharma
  • Hutchison MediPharma
  • Jiangsu Hengrui Medicine
  • Jiangsu Chia-Tai Tianqing
  • Suzhou Zelgen Biopharmaceuticals

For more information about this report visit

View Comments and Join the Discussion!